Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation.

Amado, Víctor; González-Rubio, Sandra; Zamora, Javier; Alejandre, Rafael; Espejo-Cruz, María Lola; Linares, Clara; Sánchez-Frías, Marina; García-Jurado, Gema; Montero, José Luis; Ciria, Rubén; Rodríguez-Perálvarez, Manuel; Ferrín, Gustavo; De la Mata, Manuel

Amado, Víctor; González-Rubio, Sandra; Zamora, Javier; Alejandre, Rafael; Espejo-Cruz, María Lola; Linares, Clara; Sánchez-Frías, Marina; García-Jurado, Gema; Montero, José Luis; Ciria, Rubén; Rodríguez-Perálvarez, Manuel; Ferrín, Gustavo; De la Mata, Manuel.

Afiliação

Amado V; Department of Hepatology and Liver Transplantation, Reina Sofía University Hospital, 14004 Córdoba, Spain.
González-Rubio S; Maimónides Institute of Biomedical Research (IMIBIC), University of Córdoba, 14004 Córdoba, Spain.
Zamora J; Maimónides Institute of Biomedical Research (IMIBIC), University of Córdoba, 14004 Córdoba, Spain.
Alejandre R; Centro de Investigación Biomédica en Red de Enfermedades hepáticas y digestivas (CIBERehd), 28029 Madrid, Spain.
Espejo-Cruz ML; Department of Hepatology and Liver Transplantation, Reina Sofía University Hospital, 14004 Córdoba, Spain.
Linares C; Maimónides Institute of Biomedical Research (IMIBIC), University of Córdoba, 14004 Córdoba, Spain.
Sánchez-Frías M; Department of Hepatology and Liver Transplantation, Reina Sofía University Hospital, 14004 Córdoba, Spain.
García-Jurado G; Maimónides Institute of Biomedical Research (IMIBIC), University of Córdoba, 14004 Córdoba, Spain.
Montero JL; Maimónides Institute of Biomedical Research (IMIBIC), University of Córdoba, 14004 Córdoba, Spain.
Ciria R; Maimónides Institute of Biomedical Research (IMIBIC), University of Córdoba, 14004 Córdoba, Spain.
Rodríguez-Perálvarez M; Centro de Investigación Biomédica en Red de Enfermedades hepáticas y digestivas (CIBERehd), 28029 Madrid, Spain.
Ferrín G; Pathology Department, Reina Sofía University Hospital, 14004 Córdoba, Spain.
De la Mata M; Maimónides Institute of Biomedical Research (IMIBIC), University of Córdoba, 14004 Córdoba, Spain.

Cancers (Basel) ; 13(10)2021 May 19.

Article em En | MEDLINE | ID: mdl-34069569

ABSTRACT

ABSTRACT

BACKGROUND:

In patients with hepatocellular carcinoma (HCC), a complete clearance of circulating tumor cells (CTCs) early after liver transplantation (LT) or surgical resection (LR) could prevent tumor recurrence.

METHODS:

prospective pilot study including patients with HCC who underwent LR or LT from September 2017 to May 2020. Enumeration of CTCs was performed in peripheral blood samples (7 mL) using the Isoflux® system (Fluxion Biosciences) immediately before surgery, at post-operative day 5 and at day 30. A clinically relevant number of CTCs was defined as >30 CTCs/sample.

RESULTS:

41 HCC patients were included (mean age 58.7 ± 6.3; 82.9% male). LR was performed in 10 patients (24.4%) and 31 patients (75.6%) underwent LT. The main etiology of liver disease was chronic hepatitis C (31.7%). Patients undergoing LR and LT were similar in terms of preoperative CTC count (p = 0.99), but clearance of CTCs within the first month was more pronounced in the LT group. Clusters of CTCs at baseline were associated with incomplete clearance of CTCs at day 30 (54.2% vs. 11.8%, p = 0.005), which in turn impacted negatively on survival (p = 0.038).